Search Result

Results for "

complex 2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (2) Bacterial (1) CDK (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (1) Histone Methyltransferase (10) Isotope-Labeled Compounds (1) PROTACs (4)
By Research Areas:	Cancer (17) Infection (1)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Arp2/3 Complex

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15777S1

Ribociclib-d8 LEE011-d₈	CDK	Cancer
Ribociclib-d₈ is the deuterium labeled Ribociclib[1]. Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[2].

HY-132970

EED ligand 1	Histone Methyltransferase	Cancer
EED ligand 1 is a diverse, potent, and efficacious inhibitor that target the *EED subunit of the polycomb repressive complex 2* (PRC2)** methyltransferase.

HY-101512

A-395 1 Publications Verification	Histone Methyltransferase	Cancer
A-395 is an antagonist of *polycomb repressive complex 2* (PRC2)** protein-protein interactions that potently inhibits the trimeric PRC2 complex (EZH2-EED-SUZ12) with an IC₅₀ of 18 nM .

HY-130708

UNC6852 2 Publications Verification	Histone Methyltransferase PROTACs	Cancer
UNC6852 is a selective *polycomb repressive complex 2* (PRC2) degrader based on PROTAC and contains an EED (embryonic ectoderm development) ligand and a von Hippel-Lindau ligand, with an IC₅₀** of 247 nM for EED .

HY-100846

JQEZ5 3 Publications Verification	Histone Methyltransferase	Cancer
JQEZ5 is a potent and selective EZH2 lysine methyltransferase inhibitor. JQEZ5 SAM-competitively inhibits *polycomb repressive complex 2* (PRC2) with an IC₅₀** of 80 nM. JQEZ5 has anti-tumor effects .

HY-158102

ORIC-944	Others	Cancer
ORIC-944 is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). ORIC-944 is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer.

HY-130614

PROTAC EED degrader-1	PROTACs Histone Methyltransferase	Cancer
PROTAC EED degrader-1 is a von Hippel-Lindau-based PROTAC targeting EED with a pK_D of 9.02. PROTAC EED degrader-1 is a polycomb repressive complex 2 (PRC2) inhibitor (pIC₅₀=8.17) targeting the EED subunit .

HY-130615

PROTAC EED degrader-2	PROTACs Histone Methyltransferase	Cancer
PROTAC EED degrader-2 is a von Hippel-Lindau-based PROTAC targeting EED with a pK_D of 9.27. PROTAC EED degrader-2 is a polycomb repressive complex 2 (PRC2) inhibitor (pIC₅₀=8.11) targeting the EED subunit .

HY-B0334AS1

Sulbactam-d2 sodium CP45899-d₂ sodium	Bacterial Antibiotic	Infection
Sulbactam-d₂ (sodium) is the deuterium labeled Sulbactam sodium[1]. Sulbactam (CP45899) sodium is a competitive, irreversible beta-lactamase inhibitor. Sulbactam sodium shows antimicrobial activity against multidrug-resistant (MDR) acinetobacter calcoaceticus--Acinetobacter baumannii (Acb) complex[2][3].

HY-114299S

Salcaprozate-d4 sodium SNAC-d₄ sodium	Isotope-Labeled Compounds	Others
Salcaprozate-d4 (sodium) is a deuterated labeled Salcaprozate (sodium) . Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation .

HY-158102A

ORIC-944 TFA	Others	Cancer
ORIC-944 TFA is the TFA salt form of ORIC (HY-158102). ORIC-944 TFA is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). ORIC-944 TFA is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer .

HY-101117

EED226 5+ Cited Publications	Histone Methyltransferase	Cancer
EED226 is a polycomb repressive complex 2 (PRC2) inhibitor, which binds to the K27me3-pocket on embryonic ectoderm development (EED) and shows strong antitumor activity in xenograft mice model . EED226 is a potent, selective, and orally bioavailable EED inhibitor . EED226 inhibits PRC2 with an IC₅₀ of 23.4 nM when the H3K27me0 peptide is used as a substrate in the in vitro enzymatic assays .

HY-124660A

A-395N	Endogenous Metabolite	Others
A-395N serves as a control probe for A-395, a highly potent and selective chemical probe targeting the polycomb protein EED, a key player in Polycomb repressive complex 2 (PRC2) responsible for transcriptional repression via histone H3K27 methylation. While A-395N bears structural similarities to A-395, it demonstrates no pharmacological activity in biochemical or cellular assays, making it an ideal control compound.

HY-13803

Tazemetostat Maximum Cited Publications 59 Publications Verification EPZ-6438; E-7438	Histone Methyltransferase Apoptosis	Cancer
Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a K_i value of 2.5 nM. Tazemetostat inhibits EZH2 with IC₅₀s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC₅₀ of 4 nM. Tazemetostat also inhibits EZH1 with an IC₅₀ of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells .

HY-101508

GNA002	Histone Methyltransferase	Cancer
GNA002 is a highly potent, specific and covalent EZH2 (Enhancer of zeste homolog 2) inhibitor with an IC₅₀ of 1.1 μM. GNA002 can specifically and covalently bind to Cys668 within the EZH2-SET domain, triggering EZH2 degradation through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination. GNA002 efficiently reduces EZH2-mediated H3K27 trimethylation, reactivates polycomb repressor complex 2 (PRC2)-silenced tumor suppressor genes .

HY-13803R

Tazemetostat (Standard)	Histone Methyltransferase Apoptosis	Cancer
Tazemetostat (Standard) is the analytical standard of Tazemetostat. This product is intended for research and analytical applications. Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a K_i value of 2.5 nM. Tazemetostat inhibits EZH2 with IC₅₀s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC₅₀ of 4 nM. Tazemetostat also inhibits EZH1 with an IC₅₀ of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells .

HY-160924

MS147	PROTACs E1/E2/E3 Enzyme	Cancer
MS147 is a VHL-based PROTAC degrader of PRC1 (Polycomb Repressive Complex 1). The dissociation constants (Kd) of MS147 for EED (Embryonic Ectoderm Development) and VHL (Von Hippel-Lindau) are 3.0 μM and 450 nM, respectively. MS147 specifically binds to the EED protein through its EED-binding moiety; EED is a core component of PRC2 (Polycomb Repressive Complex 2) and interacts with the core components of PRC1, BMI1 (B-lymphoma Mo-MLV insertion region 1 homolog) and RING1B (Ring Finger Protein 1B). By this binding, MS147 is able to recruit BMI1 and RING1B near to VHL. Through the degradation of BMI1 and RING1B, MS147 reduces the level of H2AK119ub (histone H2A lysine 119 ubiquitination), affecting the proliferation of cancer cells. (Blue: VHL ligand (HY-125845), Black: linker ; Pink: PRC1 ligand (HY-158771)) .

Cat. No.	Product Name	Target	Research Area

HY-P2254

H3K27(Me3) (15-34)	Peptides	Cancer
H3K27(Me3) (15-34), a histone peptide, is a repressive chromatin mark derived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me) .

HY-P2252

H3K27(Me) (15-34)	Peptides	Cancer
H3K27(Me) (15-34), a histone peptide, is a repressive chromatin markderived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me) .

HY-P2253

H3K27(Me2) (15-34)	Peptides	Cancer
H3K27(Me2) (15-34), a histone peptide, is a repressive chromatin mark derived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me) .

Cat. No.	Product Name	Chemical Structure

HY-15777S1

Ribociclib-d8
Ribociclib-d₈ is the deuterium labeled Ribociclib[1]. Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[2].

HY-B0334AS1

Sulbactam-d2 sodium
Sulbactam-d₂ (sodium) is the deuterium labeled Sulbactam sodium[1]. Sulbactam (CP45899) sodium is a competitive, irreversible beta-lactamase inhibitor. Sulbactam sodium shows antimicrobial activity against multidrug-resistant (MDR) acinetobacter calcoaceticus--Acinetobacter baumannii (Acb) complex[2][3].

HY-114299S

Salcaprozate-d4 sodium
Salcaprozate-d4 (sodium) is a deuterated labeled Salcaprozate (sodium) . Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation .

Salcaprozate-d4 sodium

Salcaprozate-d4 (sodium) is a deuterated labeled Salcaprozate (sodium) . Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80984

	Cytokeratin 5 Antibody CK-5; CK5; Cytokeratin-5; Cytokeratin5; DDD; DDD1; EBS2; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types; K2C5_HUMAN; K5; keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types); Keratin 5; Keratin ; keratin complex 2, basic, gene 5; keratin, type II cytoskeletal 5 ; Keratin-5; Keratin5; KRT 5; Krt5; KRT5A; type II cytoskeletal 5 ; Type-II keratin Kb5;	WB, IHC-P, ICC/IF, FC	Human, Mouse, Rat
	Cytokeratin 5 Antibody is an unconjugated, approximately 62 kDa, rabbit-derived, anti-Cytokeratin 5 monoclonal antibody. Cytokeratin 5 Antibody can be used for: WB, IHC-P, IF-Tissue, IF-Cell, FC expriments in human, mouse, rat background without labeling.

HY-P83361

	AP2M1 Antibody (YA3106) AP-2 complex subunit mu; AP-2 mu chain; Adapter-related protein complex 2 subunit mu; Adaptin-mu2; Clathrin assembly protein complex 2 mu medium chain; Clathrin coat assembly protein AP50	WB	Human, Mouse, Rat
	AP2M1 Antibody (YA3106) is a biotin-conjugated non-conjugated IgG antibody, targeting AP2M1, with a predicted molecular weight of 50 kDa (observed band size: 50 kDa). AP2M1 Antibody (YA3106) can be used for WB experiment in human, mouse, rat background.

HY-P82368

	Phospho-AP2M1 (Thr156) Antibody (YA2113) AP-2 complex subunit mu; AP-2 mu chain; Adapter-related protein complex 2 subunit mu; Adaptin-mu2; Clathrin assembly protein complex 2 mu medium chain; Clathrin coat assembly protein AP50	WB	Human
	Phospho-AP2M1 (Thr156) Antibody (YA2113) is a biotin-conjugated non-conjugated IgG antibody, targeting Phospho-AP2M1 (Thr156), with a predicted molecular weight of 50 kDa (observed band size: 50 kDa). Phospho-AP2M1 (Thr156) Antibody (YA2113) can be used for WB experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.